Hypersensitivity, Autoimmunity, Immunodeficiencies, and Vaccines

Hypersensitivity Reactions

Hypersensitivity is an exaggerated or inappropriate immune response to an antigen that would normally be harmless. These reactions can cause damage to the host tissues. They are classified into four main types, known as Gell and Coombs classification. Understanding these types is crucial for diagnosing and managing various immune-related disorders.

Type I Hypersensitivity (Immediate Hypersensitivity)

This is the most common type of hypersensitivity, often referred to as allergy. It occurs within minutes of exposure to an allergen (a substance that causes an allergic reaction). The mechanism involves IgE antibodies.

• Sensitization: Upon first exposure to an allergen, B cells differentiate into plasma cells that produce allergen-specific IgE antibodies. These IgE antibodies bind to the surface of mast cells and basophils.
• Re-exposure: On subsequent exposure, the allergen binds to the IgE antibodies already attached to mast cells and basophils. This cross-linking triggers the degranulation of these cells, releasing inflammatory mediators like histamine, leukotrienes, and prostaglandins.
• Clinical Manifestations: The effects of these mediators include vasodilation, increased vascular permeability, smooth muscle contraction, and mucus secretion, leading to symptoms like hives, itching, swelling, bronchoconstriction (asthma), rhinitis (hay fever), and in severe cases, anaphylaxis.

Examples: Allergic asthma, hay fever, food allergies (e.g., to peanuts, shellfish), insect sting allergies, and anaphylaxis.

Type II Hypersensitivity (Cytotoxic Hypersensitivity)

This type involves antibodies (IgG or IgM) that bind to antigens on the surface of host cells or in the extracellular matrix. This binding leads to cell damage or dysfunction through several mechanisms:

• Complement Activation: The antibody-antigen complex activates the complement system, leading to the formation of the membrane attack complex (MAC), which lyses the target cell.
• Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Cells like Natural Killer (NK) cells recognize the antibody bound to the target cell and release cytotoxic granules to kill it.
• Opsonization and Phagocytosis: Antibodies and complement components (like C3b) coat the target cell, marking it for destruction by phagocytes (macrophages, neutrophils).
• Receptor Blockade or Stimulation: Antibodies can interfere with the normal function of cell surface receptors, either by blocking their ligands or by inappropriately stimulating them.

Examples: Transfusion reactions (ABO incompatibility), Hemolytic disease of the newborn (Rh incompatibility), certain autoimmune diseases like Myasthenia Gravis (acetylcholine receptor antibodies) and Graves' disease (TSH receptor antibodies).

Type III Hypersensitivity (Immune Complex Hypersensitivity)

This reaction occurs when soluble antigens (e.g., from bacteria, viruses, or self-antigens) form complexes with circulating antibodies (IgG or IgM). These immune complexes deposit in tissues, particularly in small blood vessels, joints, and glomeruli.

• Deposition: The deposited immune complexes activate the complement system and attract inflammatory cells, especially neutrophils.
• Inflammation: Neutrophils release lysosomal enzymes and reactive oxygen species, causing tissue damage, inflammation, and vasculitis.

Examples: Systemic Lupus Erythematosus (SLE), post-streptococcal glomerulonephritis, serum sickness (reaction to foreign serum proteins), and rheumatoid arthritis.

Type IV Hypersensitivity (Delayed Hypersensitivity)

Unlike the other types, Type IV hypersensitivity is mediated by T cells (specifically Th1 cells and CTLs), not antibodies. It is a delayed reaction, typically appearing 24-72 hours after exposure to the antigen.

• Antigen Presentation: Antigens are processed by antigen-presenting cells (APCs) like macrophages, which then present them to T cells.
• T cell Activation: Sensitized T cells (memory T cells) are activated upon re-exposure to the antigen.
• Cytokine Release and Inflammation: Activated Th1 cells release cytokines (e.g., IFN-γ, TNF-α) that recruit and activate macrophages, leading to inflammation and tissue damage. Cytotoxic T lymphocytes (CTLs) can directly kill antigen-bearing cells.

Examples: Tuberculin skin test (Mantoux test), contact dermatitis (e.g., poison ivy, nickel allergy), and granuloma formation in chronic infections like tuberculosis.

Autoimmunity

Autoimmunity is a condition where the immune system mistakenly attacks the body's own tissues. Normally, the immune system distinguishes between "self" and "non-self" through a process called self-tolerance. When this tolerance breaks down, self-reactive lymphocytes (T cells and B cells) are activated, leading to autoimmune diseases.

Mechanisms of Breakdown of Self-Tolerance:

• Genetic Predisposition: Certain genes, particularly those in the Major Histocompatibility Complex (MHC, or HLA in humans), are associated with an increased risk of autoimmune diseases.
• Environmental Triggers: Infections (viruses, bacteria), trauma, exposure to certain chemicals or drugs can trigger or exacerbate autoimmunity. Molecular mimicry, where microbial antigens resemble self-antigens, can lead to cross-reactivity.
• Hormonal Factors: Autoimmune diseases are often more common in women, suggesting a role for sex hormones.
• Defects in Immune Regulation: Impaired function of regulatory T cells (Treg) or other immune suppressive mechanisms can allow self-reactive lymphocytes to survive and proliferate.

Examples of Autoimmune Diseases:

Disease	Target Autoantigen	Affected Tissue/Organ	Type of Hypersensitivity (Often)
Rheumatoid Arthritis	Joint synovium components (e.g., IgG	Synovial joints	Type III, Type IV
Systemic Lupus Erythematosus (SLE)	Nuclear antigens (DNA, histones, etc.)	Multiple organs (skin, joints, kidneys, CNS, etc.)	Type II, Type III
Type 1 Diabetes Mellitus	Pancreatic beta-cell antigens (e.g., insulin, GAD)	Pancreatic beta cells	Type IV
Graves' Disease	Thyroid-stimulating hormone (TSH) receptor	Thyroid gland	Type II
Myasthenia Gravis	Acetylcholine receptor (AChR)	Neuromuscular junction	Type II
Multiple Sclerosis (MS)	Myelin basic protein (MBP) and other myelin components	Central nervous system (CNS) myelin	Type IV

Diagnosis and Treatment: Diagnosis often involves clinical symptoms, autoantibody testing (e.g., ANA, anti-dsDNA, rheumatoid factor), and sometimes tissue biopsies. Treatment focuses on managing symptoms, reducing inflammation, and suppressing the immune response using corticosteroids, immunosuppressive drugs, and biologics.

Immunodeficiencies

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious diseases is compromised or entirely absent. They can be broadly classified into primary (congenital) and secondary (acquired) immunodeficiencies.

Primary Immunodeficiencies (PID)

These are genetic disorders resulting from defects in specific components of the immune system. They are often diagnosed in infancy or early childhood. There are over 450 different types of PIDs.

• Severe Combined Immunodeficiency (SCID): A group of rare genetic disorders characterized by a profound lack of functional T cells, and often B cells and NK cells. Infants with SCID are highly susceptible to severe infections and typically require hematopoietic stem cell transplantation or gene therapy for survival.
• X-linked Agammaglobulinemia (XLA): Affects primarily males, caused by a defect in the BTK gene, leading to a severe deficiency of B cells and antibodies.
• Common Variable Immunodeficiency (CVID): Characterized by low levels of IgG and often IgA and/or IgM, with impaired antibody production in response to infection. It is the most common symptomatic PIDs.
• DiGeorge Syndrome (22q11.2 deletion syndrome): Affects T cell development due to a defective thymus.
• Wiskott-Aldrich Syndrome (WAS): An X-linked disorder characterized by eczema, thrombocytopenia (low platelet count), and recurrent infections due to defects in T cell and B cell signaling.
• Deficiencies in Complement System: Affects the ability to clear pathogens and immune complexes.
• Deficiencies in Phagocytic Cells: Such as Chronic Granulomatous Disease (CGD), where neutrophils cannot effectively kill ingested microbes.

Key Features of PIDs: Frequent and recurrent infections, infections with unusual organisms or severity, poor response to standard antibiotic treatment, failure to thrive, and family history.

Secondary Immunodeficiencies (Acquired)

These are caused by external factors that damage or suppress the immune system. They are more common than primary immunodeficiencies.

• Acquired Immunodeficiency Syndrome (AIDS): Caused by the Human Immunodeficiency Virus (HIV), which primarily infects and destroys CD4+ T helper cells, crippling the adaptive immune response.
• Malnutrition: Protein-energy malnutrition is a major cause of secondary immunodeficiency worldwide, affecting various aspects of the immune system.
• Cancer Chemotherapy and Radiation Therapy: These treatments suppress bone marrow activity, leading to a decrease in white blood cells, including lymphocytes and neutrophils.
• Organ Transplantation and Autoimmune Diseases: Immunosuppressive drugs are used to prevent rejection or manage autoimmune conditions, which also weakens the immune system.
• Certain Infections: Besides HIV, infections like measles can temporarily suppress the immune system.
• Aging: Immune function naturally declines with age (immunosenescence).
• Splenectomy: Removal of the spleen increases susceptibility to encapsulated bacteria.

Management: Treatment depends on the specific deficiency and may include prophylactic antibiotics, immunoglobulin replacement therapy (IVIG), hematopoietic stem cell transplantation (for severe PIDs), and management of underlying causes.

Vaccines

Vaccines are biological preparations that provide active acquired immunity to a particular infectious disease. They typically contain an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins.

How Vaccines Work:

• Stimulation of Immune Response: When a vaccine is administered, it introduces antigens to the immune system without causing disease.
• Primary Immune Response: The immune system recognizes these antigens as foreign and mounts a primary response. This involves the activation of B cells to produce antibodies and T cells (including helper T cells and cytotoxic T cells). Memory B cells and memory T cells are generated.
• Immunological Memory: These memory cells provide long-lasting protection. If the vaccinated individual is later exposed to the actual pathogen, the immune system can mount a rapid and stronger secondary response, preventing or significantly reducing the severity of the disease.

Types of Vaccines:

1. Live-Attenuated Vaccines: Contain weakened versions of the live virus or bacteria that can still replicate but do not cause disease (or cause a very mild form). They provide strong, long-lasting immunity, often resembling natural infection.
   • Examples: Measles, Mumps, Rubella (MMR), Varicella (chickenpox), Oral Polio Vaccine (OPV), BCG (tuberculosis).
2. Inactivated (Killed) Vaccines: Contain whole pathogens that have been killed by heat or chemicals. They cannot replicate but still contain antigens. Immunity is generally weaker and may require multiple doses (boosters).
   • Examples: Inactivated Polio Vaccine (IPV), Hepatitis A, Rabies, most Influenza vaccines.
3. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines: These vaccines use only specific pieces of the pathogen, such as its proteins or sugars.
   • Subunit: Use only a specific protein (e.g., Hepatitis B vaccine).
   • Recombinant: Antigens are produced using recombinant DNA technology (e.g., Hepatitis B, HPV vaccine).
   • Polysaccharide: Use chains of sugar molecules from the outer coat of certain bacteria (e.g., Pneumococcal Polysaccharide Vaccine - PPSV23). These are less immunogenic in young children.
   • Conjugate: Polysaccharide antigens are chemically linked to a carrier protein to enhance the immune response, especially in infants and young children (e.g., Haemophilus influenzae type b (Hib), Pneumococcal Conjugate Vaccine (PCV13), Meningococcal conjugate vaccines).
4. Toxoid Vaccines: Used for diseases caused by bacterial toxins. The vaccines contain inactivated toxins (toxoids) that trigger immunity against the toxin, not the bacteria itself.
   • Examples: Diphtheria and Tetanus vaccines (often given in combination, e.g., DTaP, Tdap).
5. mRNA Vaccines: A newer type that uses messenger RNA (mRNA) to instruct human cells to make a specific antigen (e.g., spike protein of SARS-CoV-2). The immune system then responds to this antigen. The mRNA is degraded quickly by the body.
   • Examples: Pfizer-BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine.
6. Viral Vector Vaccines: Use a modified version of a different virus (the vector) to deliver genetic instructions for making an antigen.
   • Examples: AstraZeneca COVID-19 vaccine, Johnson & Johnson COVID-19 vaccine.

Herd Immunity (Community Immunity): When a sufficiently large proportion of a population is immune to an infectious disease (either through vaccination or prior infection), it becomes difficult for the disease to spread from person to person. This indirectly protects individuals who are not immune, such as infants too young to be vaccinated or immunocompromised individuals. The threshold for herd immunity varies by disease.

Adjuvants: Some vaccines contain adjuvants, substances that help create a stronger immune response to the vaccine. They enhance the vaccine's immunogenicity. Aluminum salts are common examples.

Vaccine Safety: Vaccines undergo rigorous testing and monitoring for safety and efficacy before and after they are approved for use. While side effects can occur, they are typically mild and temporary (e.g., soreness at the injection site, mild fever). Serious adverse events are extremely rare. The benefits of vaccination in preventing serious diseases far outweigh the risks.